1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Nasdaq's Hearings Panel granted Australian Oilseeds an extension to regain compliance with its $2.5 million minimum stockholders' equity rule, and allowed its shares and warrants to keep trading on Nasdaq through September 30, 2025. The company reported $2.6 million in shareholder equity as of its July 22, 2025 hearing, but must meet the rule by the deadline and would then face a one-year panel monitor.
Nasdaq Panel decision received August 22, 2025; listing continues through September 30, 2025, subject to meeting the equity rule by that date
Minimum stockholders' equity requirement is $2.5 million under Nasdaq Listing Rule 5450(b)(1)(A)
Company reported $2.6 million in shareholder equity as of the July 22, 2025 hearing date
Company plans to maintain minimum equity by converting additional debt and increasing revenues; a one-year panel monitor applies if compliance is regained
Chemours, DuPont and Corteva agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve pending environmental claims, including statewide PFAS claims. Chemours will pay 50% of the $875 million settlement over 25 years, about $250 million on a present value basis, and the settlement remains subject to notice, comment and court approval. Chemours also agreed to sell its rights to $150 million of potential PFAS insurance proceeds to DuPont and Corteva, which it expects to fully fund its settlement payments through at least 2030.
Settlement totals $875 million over 25 years, with pre-tax present value of about $500 million; payments begin no earlier than January 1, 2026
Chemours responsible for 50% of settlement payments, about $250 million on a present value basis
DuPont and Corteva to purchase Chemours' rights to $150 million of PFAS insurance proceeds, contingent on JCO approval
Settlement remains subject to notice and comment under New Jersey law and final court approval
On August 3, 2025, DuPont, Chemours and Corteva agreed to a proposed judicial consent order with the State of New Jersey to resolve state claims over legacy contamination, including PFAS, subject to court approval. DuPont recorded a $177 million pre-tax charge in discontinued operations in the second quarter of 2025, reflecting the net present value of $311 million, which the filing estimates as its share of the settlement payments, so the settlement adds a large cost for shareholders.
Aggregate cash payment to New Jersey of $875 million, payable over 25 years and shared under the 2021 MOU among DuPont, Chemours and Corteva.
Second-quarter 2025 pre-tax charge of $177 million within discontinued operations; DuPont's estimated share of payments has a net present value of $311 million at an 8 percent discount rate.
DuPont and Corteva will establish a $475 million Reserve Fund, and DuPont will contribute $106.5 million of a $150 million NJ Escrow tied to Chemours' share of the settlement.
First annual payment due within 30 days of court entry, and no earlier than January 31, 2026; the settlement is subject to a public comment period and the company admits no liability.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.